TW200508233A - Chk-1 inhibitors - Google Patents

Chk-1 inhibitors

Info

Publication number
TW200508233A
TW200508233A TW093115276A TW93115276A TW200508233A TW 200508233 A TW200508233 A TW 200508233A TW 093115276 A TW093115276 A TW 093115276A TW 93115276 A TW93115276 A TW 93115276A TW 200508233 A TW200508233 A TW 200508233A
Authority
TW
Taiwan
Prior art keywords
chk
inhibitors
therapy
disclosed
methods
Prior art date
Application number
TW093115276A
Other languages
English (en)
Inventor
Robert George Boyle
Hassan Julien Imogai
Michael Cherry
Alfred John Humphries
Eva Figueroa Navarro
David Rodney Owen
Natalie A Dales
Matthew Lamarche
Courtney Cullis
Alexandra E Gould
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of TW200508233A publication Critical patent/TW200508233A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • C07F7/0814—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring said ring is substituted at a C ring atom by Si

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
TW093115276A 2003-05-29 2004-05-28 Chk-1 inhibitors TW200508233A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US47416103P 2003-05-29 2003-05-29

Publications (1)

Publication Number Publication Date
TW200508233A true TW200508233A (en) 2005-03-01

Family

ID=34375204

Family Applications (1)

Application Number Title Priority Date Filing Date
TW093115276A TW200508233A (en) 2003-05-29 2004-05-28 Chk-1 inhibitors

Country Status (4)

Country Link
US (1) US20050245563A1 (zh)
AR (1) AR045689A1 (zh)
TW (1) TW200508233A (zh)
WO (1) WO2005028474A2 (zh)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101914107B (zh) * 2003-11-12 2012-03-07 第一三共株式会社 噻唑衍生物的制备方法
US20060035920A1 (en) * 2004-05-28 2006-02-16 Millennium Pharmaceuticals, Inc. Chk-1 inhibitors
CN102017525A (zh) 2005-01-06 2011-04-13 默克公司 关卡激酶抑制剂
JP2008526865A (ja) * 2005-01-06 2008-07-24 メルク エンド カムパニー インコーポレーテッド チェックポイントキナーゼの阻害剤
EP2164328B8 (en) * 2007-06-08 2013-09-11 Dart Neuroscience (Cayman) Ltd Therapeutic pyrazoloquinoline urea derivatives
US7872002B2 (en) * 2007-06-08 2011-01-18 Helicon Therapeutics, Inc. Therapeutic pyrazoloquinoline derivatives
WO2008154447A1 (en) * 2007-06-08 2008-12-18 Helicon Therapeutics, Inc. Therapeutic pyrazolonaphthyridine derivatives
ES2322121B1 (es) * 2007-12-10 2010-04-19 Consejo Superior De Investigaciones Cientificas Nuevos derivados de aminoacidos dicarboxilicos y su aplicacion en el tratamiento de enfermedades neurodegenerativas.
CN103097383B (zh) 2010-09-07 2015-09-16 安斯泰来制药株式会社 吡唑并喹啉化合物
ES2527188T3 (es) * 2011-09-26 2015-01-21 Sanofi Derivados de pirazolquinolinona, su preparación y su uso terapéutico
US9169246B2 (en) * 2011-09-26 2015-10-27 Sanofi Pyrazoloquinolinone derivatives, preparation thereof and therapeutic use thereof
JP6042060B2 (ja) * 2011-09-26 2016-12-14 サノフイ ピラゾロキノリノン誘導体、その調製および治療上の使用
US11135206B2 (en) 2015-05-26 2021-10-05 Kaohsiung Medical University Pyrazolo[4,3-c]quinoline derivatives for inhibition of β-glucuronidase
GB201516616D0 (en) * 2015-09-18 2015-11-04 Redx Pharma Plc Antibacterial compounds
CN105523955B (zh) * 2015-12-14 2018-08-17 北京嘉林药业股份有限公司 化合物及其在制备药物中的用途
MX2022015829A (es) * 2020-06-11 2023-04-05 Chdi Foundation Inc Compuestos heterocíclicos y agentes formadores de imágenes para formar la imagen de la proteína huntingtina.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3890324A (en) * 1974-04-12 1975-06-17 Lilly Co Eli 1h-pyrazolo(4,3-)quinol-4(5h)-one-3-carboxylic acids
US5192768A (en) * 1990-09-14 1993-03-09 Kyowa Hakko Kogyo Co., Ltd. Pyrazoloquinoline derivatives
US6723498B1 (en) * 1999-06-30 2004-04-20 Millennium Pharmaceuticals, Inc. Chk1 and uses thereof
UA76977C2 (en) * 2001-03-02 2006-10-16 Icos Corp Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers

Also Published As

Publication number Publication date
US20050245563A1 (en) 2005-11-03
AR045689A1 (es) 2005-11-09
WO2005028474A3 (en) 2005-06-02
WO2005028474A2 (en) 2005-03-31

Similar Documents

Publication Publication Date Title
WO2003101444A8 (en) Diarylurea compounds and derivatives as chk-1 inhibitors for the treatment of cancer
IL244803A0 (en) Human anti-beta7 antibodies and their use
MY169308A (en) Treatment of tnf? related disorders
SG148864A1 (en) Methods of treating cancer and related methods
AU2003291356A1 (en) Methods and compositions for treating cancer using proteasome inhibitors
AU2003299585A8 (en) Water-soluble products and methods of making and using the same
SG145695A1 (en) Pyridyl derivatives and their use as therapeutic agents
SG145700A1 (en) Pyridyl derivatives and their use as therapeutic agents
WO2003073999A3 (en) Pini-modulating compounds and methods of use thereof
WO2003074550A3 (en) Pin1-modulating compounds and methods of use thereof
TW200508233A (en) Chk-1 inhibitors
ZA200601293B (en) Proteasome inhibitors and methods of using the same
WO2003103571A3 (en) VACCINES AGAINST FLAVIVIRUSES
SG148182A1 (en) Antiloading compositions and methods of selecting same
MX2007002277A (es) Metodos para formar retinoides y usos de los mismos.
TW200505443A (en) Combination of SCR kinase inhibitors and chemotherapeutic agents for the treatment of proliferative diseases
MY133625A (en) Peptide deformylase inhibitors
WO2002076396A3 (en) Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
WO2004030634A3 (en) Therapeutic compositions
AU2003223538A1 (en) Methods for the treatment of cancer
AU2003223634A1 (en) Peptide deformylase inhibitors
SG144920A1 (en) Method and intermediates for the preparation of derivatives of n-(1- benzhydrylazetidin-3-yl)-n-phenylmethylsulphonamide
GB0210741D0 (en) Methods of therapy
TW200510276A (en) Calcilytic compounds
AU2576901A (en) Agents and methods for the treatment of proliferative diseases